Sharemaestro company-news research for Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
AMRX news sentiment
Amneal Pharmaceuticals, Inc. Class A Common Stock
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone73Neutral is 50
Constructive news tone
72/100 evidence confidence
100% direct company focus
6 current stories across 1 publishers
Current company news
Positive news being faded
Constructive news tone is drawn from 6 fresh independent stories, including 6 company-specific items across 1 publishers.
Latest source headline Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? finance.yahoo.com · 12 Aug 2026 15:53What supports the read
6 current stories are mapped specifically to AMRX.
Cross-story agreement is 89/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Constructive headlines are not being rewarded by price, which raises a rejection flag.
73/100
Weighted toneConstructive news tone
72/100
Evidence confidencesolid confidence
100%/100
Company focus6 direct stories
89/100
Evidence agreement11/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth70
5.57 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness80
recency-weighted evidenceAgreement89
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive headlines are not being rewarded by price, which raises a rejection flag.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trendPositive but stretched
News subjects
What is shaping the score
Earnings824 stories · 67%
Deals and strategy871 stories · 17%
Regulatory and legal841 stories · 17%
Source mix
Where the evidence comes from
finance.yahoo.com836 stories · 100%
Recurring subjects
Subjects appearing most often
Earnings4Pharma3Earnings Per Share3Earnings Estimate2Biotech2Biosimilars2Telemedicine1Specialty Medicines1Retinal Diseases1Price Target1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#187Tone
finance.yahoo.comDirect company coverage
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution and product uptake. Amneal Gains an End-to-End Biosimilar Platform Kashiv adds development and manufacturing capabilities to Amneal's existing commercialization platform. Bringing those functions together is intended to support a ste
BiosimilarsBiotechFdaM APharma
- Published
- 12 Aug 2026 15:53
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#282Tone
finance.yahoo.comDirect company coverage
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains competitive and complex launches carry regulatory and adoption risk. Valuation also sends a mixed signal, making execution central to the buy case. AMRX's 2026 Outlook Keeps Moving Higher Amneal raised 2026 net revenue guidance to $3.10-$3.20 billion from $3.05-$3.15 billion. Adjusted EB
BiosimilarsEarningsGuidancePharmaSpecialty Medicines
- Published
- 12 Aug 2026 15:51
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#387Tone
finance.yahoo.comDirect company coverage
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal Pharmaceuticals AMRX shares have gained 44.8% over the past 12 weeks, putting the durability of the advance in focus. The rally has coincided with better operating results and a higher 2026 outlook. The next leg will depend on whether earnings growth, new launches and pipeline progress can outweigh execution risks and a valuation that has moved well above AMRX's own historical norm. AMRX's Earnings Momentum Supports the Rally Second-quarter 2026 revenues rose 10% year over year to $796 million, topping the Zacks Consensus Estimate of $768 million. Adjusted earnings increased 20% to 30 c
EarningsEarnings EstimateEarnings GrowthEarnings Per ShareFda ApprovalGenerics
- Published
- 12 Aug 2026 15:49
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#484Tone
finance.yahoo.comDirect company coverage
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases. Patient enrollment is ongoing. DME is a complex, multi-factorial condition in which vascular leakage, disruption of the blood-retinal barrier, and chronic inflammatory signaling collectively contribute to retinal edema and vision loss. Year to date, Kodiak's shares have risen 55.2% compared with the industry's 6% growth.Zacks Inv
BiotechClinical TrialsEarningsEarnings Per ShareRetinal Diseases
- Published
- 11 Aug 2026 15:15
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#590Tone
finance.yahoo.comDirect company coverage
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going. Our "Recent Price Strength" screen, w
EarningsEarnings EstimatePharmaPrice Target
- Published
- 11 Aug 2026 12:55
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#645Tone
finance.yahoo.comDirect company coverage
1 Healthcare Stock Worth Your Attention and 2 We Ignore
1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over the past six months, topping the S&P 500 by 7.4 percentage points. Although these businesses have produced results, only a handful will thrive over the long term as the influx of venture capital has ushered in a new wave of competition. Taking that into account, here is one healthcare stock poised to generate sus
Earnings Per ShareHealthcarePharmaceuticalsTelemedicine
- Published
- 10 Aug 2026 12:45
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
AMRX news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
07
2026
StockStoryArchivedPositive tone
5 Insightful Analyst Questions From Amneal’s Q2 Earnings Call
- Published
- 7 Aug 2026 08:15
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
simplywall.stArchivedPositive tone
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance
- Published
- 2 Aug 2026 19:25
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
01
2026
simplywall.stArchivedPositive tone
Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure
- Published
- 1 Aug 2026 02:58
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
GuruFocus.comArchivedPositive tone
Amneal Pharmaceuticals Inc (AMRX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...
- Published
- 31 Jul 2026 08:52
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
Market sourceArchivedPositive tone
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
- Published
- 29 Jul 2026 19:39
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
TradingViewArchivedPositive tone
Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT
- Published
- 28 Jul 2026 05:59
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
StocktwitsArchivedPositive tone
AMRX: Amneal Pharmaceuticals Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas
- Published
- 25 Jul 2026 00:18
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
Seeking AlphaArchivedPositive tone
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX)
- Published
- 22 Jul 2026 10:28
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
20
2026
ad-hoc-news.deArchivedPositive tone
Molina Healthcare stock trades steadily as recent earnings and Medicaid membership growth underpin v
- Published
- 20 Jul 2026 07:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
19
2026
simplywall.stArchivedPositive tone
How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story
- Published
- 19 Jul 2026 01:13
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
11
2026
ad-hoc-news.deArchivedPositive tone
Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth
- Published
- 11 Jul 2026 00:40
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
simplywall.stArchivedPositive tone
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?
- Published
- 9 Jul 2026 10:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
MSNArchivedPositive tone
Why Amneal (AMRX) stock is trading up today
- Published
- 7 Jul 2026 10:06
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
04
2026
simplywall.stArchivedPositive tone
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced?
- Published
- 4 Jul 2026 15:48
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
TradingViewArchivedPositive tone
Why Tenet Healthcare (THC) Stock Is Up Today
- Published
- 3 Jul 2026 13:06
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
TradingViewArchivedPositive tone
Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX
- Published
- 2 Jul 2026 12:32
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
TradingViewArchivedPositive tone
Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX
- Published
- 1 Jul 2026 08:51
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
AD HOC NEWSArchivedPositive tone
Select Medical Holdings earnings calendar sets up the SEM shares, healthcare stock on NYSE draws ana
- Published
- 30 Jun 2026 09:47
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
TradingViewArchivedPositive tone
2DT Forecast — Price Target — Prediction for 2027
- Published
- 28 Jun 2026 16:41
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
Investing.com CanadaArchivedPositive tone
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com
- Published
- 25 Jun 2026 15:45
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
simplywall.stArchivedPositive tone
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
- Published
- 22 Jun 2026 23:45
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
21
2026
ZacksArchivedPositive tone
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
- Published
- 21 Jun 2026 08:23
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.